NCT00751790View on ClinicalTrials.gov

Efficacy and Safety of a Triptorelin 6-month Formulation in Patients With Advanced Prostate Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

August 31, 2007

Study Completion Date

August 31, 2007

Conditions
Prostatic Neoplasm
Interventions
DRUG

triptorelin embonate (INN)

Triptorelin embonate 22.5 mg 6 month formulation to be injected every 24 weeks

Trial Locations (1)

0157

Quintiles South Africa, Lyttelton Manor

Sponsors
All Listed Sponsors
lead

Debiopharm International SA

INDUSTRY